Marie-Sarah Rouvière

Marie-Sarah Rouvière

Auto-generated profile, based on publicly available information

Marie-Sarah Rouvière

Team Immunity and Cancer, Centre de Recherche en Cancerologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli–Calmettes, Aix–Marseille University, UM105, Marseille, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
SFStéphane Fattori
Stéphane Fattori
ARAude Le Roy
Aude Le Roy
JHJemila Houacine
Jemila Houacine
LRLucie Robert
Lucie Robert
RARiad Abes
Riad Abes
DODaniel Olive
Daniel Olive
Regulatory T cells (Treg) impede effective antitumor immunity. However, the role of Tregs in the clinical outcomes of patients with triple-negative breast cancer (TNBC) remains controversial. Here, we found that an immunosuppressive TNBC microenvironment is marked by an imbalance between effector αβCD8+ T cells and Tregs harboring hallmarks of highly suppressive effector Tregs (eTreg). Intratumoral eTregs strongly expressed PD-1 and persisted in patients with TNBC resistant to PD-1 blockade. Importantly, CD25 was the most selective surface marker of eTregs in primary TNBC and metastases compared with other candidate targets for eTreg depletion currently being evaluated in trials for patients with advanced TNBC. In a syngeneic TNBC model, the use of Fc-optimized, IL2 sparing, anti-CD25 antibodies synergized with PD-1 blockade to promote systemic antitumor immunity and durable tumor growth control by increasing effector αβCD8+ T-cell/Treg ratios in tumors and in the periphery. Together, this study provides the rationale for the clinical translation of anti-CD25 therapy to improve PD-1 blockade responses in patients with TNBC. Significance: An imbalance between effector CD8+ T cells and CD25high effector Tregs marks immunosuppressive microenvironments in αPD-1–resistant TNBC and can be reversed through effector Treg depletion to increase αPD-1 efficacy.

31 January 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
Laurent GorvelLaurent Gorvel
Laurent Gorvel
MPMarylou Panouillot
Marylou Panouillot
MRMarie-Sarah Rouvière
Marie-Sarah Rouvière
EBEmilien BILLON
Emilien BILLON
SFStéphane Fattori
Stéphane Fattori
DODaniel Olive
Daniel Olive
Cervical tumors are usually treated using surgery, chemotherapy, and radiotherapy and would benefit from immunotherapies. However, the immune microenvironment in cervical cancer remains poorly described. Tertiary lymphoid structures (TLS) were recently described as markers for better immunotherapy response and overall better prognosis in patients with cancer. We evaluated the cervical tumor immune microenvironment, specifically focusing on TLS, using combined high-throughput phenotyping, soluble factor concentration dosage in the tumor microenvironment, and spatial interaction analyses. We found that TLS presence was associated with a more inflammatory soluble microenvironment, with the presence of B cells as well as more activated macrophages and dendritic cells (DC). Furthermore, this myeloid cell activation was associated with the expression of immune checkpoints, such as PD-L1 and CD40, and the proximity of activated conventional type 2 DCs to CD8+ T cells, indicating better immune interactions and tumor control. Finally, we associated TLS presence, greater B-cell density, and activated DC density with improved progression-free survival, substantiating TLS presence as a potential prognostic marker. Our results provide evidence that TLS presence denotes cell activation and immunotherapy target expression.

14 August 2024 in Blood Advances
Verified
Journal Article
Open access
AFAnne-Charlotte Le Floch
Anne-Charlotte Le Floch
FOFlorence Orlanducci
Florence Orlanducci
Marie BénéMarie Béné
Marie Béné
AAAmira Ben Amara
Amira Ben Amara
MRMarie-Sarah Rouviere
Marie-Sarah Rouviere
DODaniel Olive
Daniel Olive
In several tumor subtypes, an increased infiltration of Vγ9Vδ2 T cells has been shown to have the highest prognostic value compared with other immune subsets. In acute myeloid leukemia (AML), similar findings have been based solely on the inference of transcriptomic data and have not been assessed with respect to confounding factors. This study aimed at determining, by immunophenotypic analysis (flow or mass cytometry) of peripheral blood from patients with AML at diagnosis, the prognostic impact of Vγ9Vδ2 T-cell frequency. This was adjusted for potential confounders (age at diagnosis, disease status, European LeukemiaNet classification, leukocytosis, and allogeneic hematopoietic stem cell transplantation as a time-dependent covariate). The cohort was composed of 198 patients with newly diagnosed (ND) AML. By univariate analysis, patients with lower Vγ9Vδ2 T cells at diagnosis had significantly lower 5-year overall and relapse-free survivals. These results were confirmed in multivariate analysis (hazard ratio [HR], 1.55 [95% confidence interval (CI), 1.04-2.30]; P = .030 and HR, 1.64 [95% CI, 1.06-2.53]; P = .025). Immunophenotypic alterations observed in patients with lower Vγ9Vδ2 T cells included a loss of some cytotoxic Vγ9Vδ2 T-cell subsets and a decreased expression of butyrophilin 3A on the surface of blasts. Samples expanded regardless of their Vγ9Vδ2 T-cell levels and displayed similar effector functions in vitro. This study confirms the prognostic value of elevated Vγ9Vδ2 T cells among lymphocytes in patients with ND AML. These results provide a strong rationale to consider consolidation protocols aiming at enhancing Vγ9Vδ2 T-cell responses.

18 August 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
Laurent GorvelLaurent Gorvel
Laurent Gorvel
MPMarylou Panouillot
Marylou Panouillot
MRMarie-Sarah Rouvière
Marie-Sarah Rouvière
EBEmilien Billon
Emilien Billon
SFStéphane Fattori
Stéphane Fattori
DODaniel Olive
Daniel Olive
Background: Cervical tumors are usually treated using surgery, chemotherapy, and radiotherapy, and would benefit from immunotherapies. However, the immune microenvironment in cervical cancer remains poorly described. Tertiary lymphoid structures (TLS) were recently described as markers for better immunotherapy response and overall better prognosis in cancer patients. Methods: We integratedly evaluated the cervical tumor immune microenvironment, and specifically TLS importance, using combined high-throughput phenotyping, soluble factor dosage, spatial interaction analyses, and statistical analyses. Results: We demonstrate that TLS presence is associated with a more inflammatory soluble microenvironment, with the presence of B cells as well as more activated macrophages and dendritic cells (DCs). Furthermore, this myeloid cell activation is associated with expression of immune checkpoints, such as PD-L1 and CD40, and close proximity of activated conventional DC2 to CD8 + T cells, therefore indicating better immune interactions and tumor control. Finally, we associate TLS presence, greater B cell density, and activated DC density to improved progression-free survival, and present it as an additional prognostic marker. Conclusion: To conclude, our results provide an exhaustive depiction of the cervical tumor immune microenvironment where TLS presence marks cell activation and immunotherapy target expression. These findings provide predictive clues for patient response to targeted immunotherapies. Significance: TLS maturation stratifies cervical cancer patients and associates with improved prognosis. TLS associate with the expression of immune checkpoints, notably in the macrophage compartment, which may represent a new therapeutic strategy.

8 July 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
SFStéphane Fattori
Stéphane Fattori
Laurent GorvelLaurent Gorvel
Laurent Gorvel
MRMarie-Sarah Rouviére
Marie-Sarah Rouviére
SGSamuel Granjeaud
Samuel Granjeaud
AAAmira Ben Amara
Amira Ben Amara
DODaniel Olive
Daniel Olive
Vγ9Vδ2 (TCRVγ9+ TCRVδ2+) T cells are promising immunotherapeutic targets with effective antitumor properties in both in vitro and preclinical models of triple-negative breast cancer (TNBC). However, no information about their potential role in the context of human TNBC progression and response to immunotherapy has been reported. One key reason for this is the scarcity of Vγ9Vδ2 T-cell infiltrates relative to their Vδ1 (TCRVδ1+) and αβCD8 (TCRαβ+ CD8αβ+) T-cell counterparts. We provide comprehensive single-cell profiling of Vγ9Vδ2 T cells from patients with TNBC, prior to and following PD-(L)1 blockade therapy. We report that baseline Vγ9Vδ2 T-cell infiltrate expressing a unique cytotoxic type I phenotype could be associated with improved survival in patients with TNBC. Vγ9Vδ2 T cells harboring characteristics of enhanced antitumor activity (KLRC1+) were further associated with improved response to PD-(L)1 blockade therapy in patients with TNBC. Vγ9Vδ2 T cells had low expression levels of T-cell exhaustion (PD-1LowTOXLow) and T-cell receptor signaling hallmarks compared with Vδ1 and αβCD8 T cells, along with skewed differentiation profiles toward early effector memory phenotypes, both before and after anti–PD-1 therapy in TNBC tumors. Consistently, we observed limited activity of anti–PD-1 on tumor-infiltrating Vγ9Vδ2 T cells. In vitro, the use of anti–butyrophilin-3A antibodies in addition to anti–PD-1 reinvigorated the cytotoxic type I functions of peripheral Vγ9Vδ2 T cells from patients with breast cancer. Together, these data provide a rationale for Vγ9Vδ2 T cell–based combination therapy in patients with TNBC.

11 October 2022 in médecine/sciences
Verified
Journal Article
Open access
PDF file
Laurent GorvelLaurent Gorvel
Laurent Gorvel
ACAnne-Sophie Chretien
Anne-Sophie Chretien
SFStéphane Fattori
Stéphane Fattori
MRMarie-Sarah Rouviere
Marie-Sarah Rouviere
PRPhilippe Rochigneux
Philippe Rochigneux
DODaniel Olive
Daniel Olive
Médecine/sciences (M/S), revue internationale dans le domaine de la recherche biologique, médicale et en santé